Clinical trial
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa…
NCT00054899 · Epimmune, Industry · Completed
Key facts
| NCT number | NCT00054899 |
|---|---|
| Title | An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer |
| Official title | An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Epimmune, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Lung Neoplasm |
| Intervention type | Biological |
| Interventions | EP2101 |
| Enrollment | 18 |
| Start date | Jan 1, 2003 |
| First posted | Feb 14, 2003 |
| Last update posted | Mar 24, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: